<SEC-DOCUMENT>0000950170-23-053894.txt : 20231018
<SEC-HEADER>0000950170-23-053894.hdr.sgml : 20231018
<ACCEPTANCE-DATETIME>20231018113117
ACCESSION NUMBER:		0000950170-23-053894
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231018
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231018
DATE AS OF CHANGE:		20231018

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Candel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001841387
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				522214851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40629
		FILM NUMBER:		231331329

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		617-916-5445

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Candel Therapeutics, Inic.
		DATE OF NAME CHANGE:	20210120
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cadl-20231018.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-10-18T08:23:35.6087+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:cadl="http://www.candeltx.com/20231018" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_5b213b4e-faa2-40c8-b467-d308abbf3579" name="dei:AmendmentFlag" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_c63f2a9c-25fc-4bb0-a292-64e4c12fb164" name="dei:EntityCentralIndexKey" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a">0001841387</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cadl-20231018.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001841387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-18</xbrli:startDate><xbrli:endDate>2023-10-18</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double;padding-top:1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_f012b128-66e5-4e45-a436-d86b8d3e97a9" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_bd957721-00a8-4e6a-862c-26911a8bd8a1" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">October 18, 2023</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_8841de57-9ee6-4dac-99ce-949c3e0012cb" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:'Times New Roman',serif;min-width:fit-content;">CANDEL THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_778ce643-7e59-4682-bb17-35dba6ca534a" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_134e08b9-9b3b-4425-bd87-4169f825d4e3" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">001-40629</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_f072fa2e-efff-4e50-b147-4b87f7297534" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">52-2214851</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">(IRS Employer</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_c8b00f95-9fc7-4a6b-8366-b9136a949a0d" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">117 Kendrick St</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">., </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_22d027b6-f73d-49a5-8bd0-5ad09b0c6db4" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Suite 450</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_71a31c3d-8f90-4aec-a5a8-cd360fe29449" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Needham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_b370751d-4500-4837-87d6-3cd8547b6e56" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:4pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_8c341ba3-9206-4a94-8c2d-3652210b5438" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">02494</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:4pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code: </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_5da723cb-bd83-4142-b948-e4ac764121fb" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">(617)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_55c5dbce-f0c3-4987-b212-7beafaee0d75" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">916-5445</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Not Applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"></td>
    <td style="width:96%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_e5cb253d-2e57-4186-8152-7902df8578b7" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_25fb8ca8-8525-4458-b7fa-ae3b79fe7834" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_9aaf36e7-2e2b-4cf7-966f-edc72d5528b9" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_117cc848-3754-40e6-97d2-9e9a0e158640" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"></td>
    <td style="width:1%;"></td>
    <td style="width:15%;"></td>
    <td style="width:1%;"></td>
    <td style="width:45%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_c6b76e03-d395-41b0-892e-04d845258ec4" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Common Stock, $0.01 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_0d6a56ce-2a73-496b-b2c3-c3ee00727a80" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">CADL</span></ix:nonNumeric></span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_9525bc29-bbbc-4116-a798-ac8b723a6463" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x2009;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x2009;240.12b-2 of this chapter).</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:8pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_20b3a2b0-81b9-4adc-8c07-4fb5fe12b9b9" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><ix:nonNumeric id="F_17c9597d-4e13-4d96-ac67-0061336087f0" contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">On October 18, 2023, Candel Therapeutics, Inc. (the &#x201c;Company&#x201d;) issued a press release announcing a Nature publication showing extended survival associated with immune activation in patients with recurrent high-grade glioma treated with CAN-3110.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">A copy of the full press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are furnished and shall not be deemed to be &#x201c;filed&#x201d; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.08%;"></td>
    <td style="width:2.02%;"></td>
    <td style="width:90.9%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:'Times New Roman',serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;99.1</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span><a href="cadl-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Press Release dated October 18, 2023</span></a></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;104</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"></td>
    <td style="width:5.04%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:46.46%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Candel Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Date: October 18, 2023</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">/s/ Paul Peter Tak</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Paul Peter Tak, M.D., Ph.D., FMedSci</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cadl-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12.5pt;font-family:'Times New Roman',serif;font-style:italic;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img160460863_0.jpg" alt="img160460863_0.jpg" style="width:222px;height:98px;">&#160;</p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Arial',sans-serif;min-width:fit-content;">Candel Therapeutics Announces </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Arial',sans-serif;font-style:italic;min-width:fit-content;">Nature</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Arial',sans-serif;min-width:fit-content;"> Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;font-style:italic;min-width:fit-content;">CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single therapeutic</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;font-style:italic;min-width:fit-content;">In a first-in-human clinical trial of CAN-3110 in recurrent high-grade glioma, CAN-3110 was well tolerated and treatment was associate with improved survival</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;font-style:italic;min-width:fit-content;">Positive HSV-1 serology, before or after CAN-3110 injection, was a predictor of response and was associated with improved survival</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;font-style:italic;min-width:fit-content;">Increased infiltrating immune cells in the tumor microenvironment and expansion of the T cell repertoire after treatment were associated with improved survival</font></div></div>
  <p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">NEEDHAM, Mass., October 18, 2023 (GLOBE NEWSWIRE) -- </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;font-style:italic;min-width:fit-content;">Nature</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> published results from the ongoing first-in-human phase 1 investigator-sponsored clinical trial of CAN-3110, a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate, in patients with recurrent high-grade glioma (HGG), of which 86.7% were glioblastoma, that had returned after standard of care (SoC) treatment.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">The study is being conducted in a collaboration between Brigham and Women&#x2019;s Hospital and Candel. The publication titled &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;font-style:italic;min-width:fit-content;">Clinical trial links oncolytic immunoactivation to survival in glioblastoma</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">&#x201d; can be accessed at </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">https://www.nature.com/articles/s41586-023-06623-2</font></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Key findings of the manuscript: Tolerability of a single injection of CAN-3110 in recurrent HGG with no dose limiting toxicity reported, improved median overall survival in 41 patients treated in Arm A (11.6 months as of data cutoff in October 2022) and correlation between anti-HSV-1 serology and survival. Importantly, CAN-3110 treatment was associated with a significant increase in immune cells in the tumor</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">microenvironment and in the peripheral blood. The activation of both local and systemic immune response, including the expansion of the T-cell repertoire diversity as well as HSV-1 immune status, correlate with survival suggesting that CAN-3110 can enhance anti-cancer immune responses even in immunosuppressive tumor microenvironments.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">&#x201c;There is an urgent need to develop novel therapies for recurrent HGG,&#x201d; said E. Antonio Chiocca, MD, PhD, Head of Department of Neurosurgery at Brigham and Women&#x2019;s Hospital, Professor at Harvard Medical School, and Principal Investigator of the clinical trial. &#x201c;Failure of standard of care and conventional immunotherapy in recurrent HGG largely resides in the inability of available therapies to efficiently activate the immune system in the cold tumor microenvironment that is characteristic for this condition. In this manuscript we provide evidence that, after a single injection, the direct oncolytic activity combined with the ability of CAN-3110 to elicit a strong anti-tumoral response, resulted in conversion of the cold tumor microenvironment and induced a systemic immune response linked to improved patient survival.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Dr. Chiocca continued, &#x201c;Prolonged survival was associated with HSV-1 seropositivity, either before or after CAN-3110 treatment. Importantly, approximately 30% of seronegative patients at baseline seroconverted after CAN-3110 treatment. Those patients also exhibited increased survival suggesting the possibility of leveraging this mechanism and further improving survival upon multiple injections.&#x201d;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">&#x201c;This high impact publication detailing results from 41 patients in the phase 1 clinical trial of CAN-3110 is an important validation of how Candel, in collaboration with academic leaders in the field, are working to address the critical challenges in recurrent HGG,&#x201d; said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. &#x201c;In the clinical study, we observed a nearly doubling of the expected median overall survival after a single CAN-3110 injection, compared to historical reports of less than 6 to 9 months. We reported transformative improvements after a single injection of CAN-3110 in patients affected by aggressive tumors who had failed multiple resections, chemotherapy and radiotherapy.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Dr. Tak continued, &#x201c;As a next step, we are currently evaluating the effects of multiple CAN-3110 injections in recurrent HGG, supported by the Break Through Cancer foundation. The data reported in the manuscript reinforce our confidence in CAN-3110 and its potential to change disease outcomes in difficult-to-treat solid tumors that express Nestin. In the future, we could possibly expand the development of this agent into other indications characterized by Nestin expression, such as triple negative breast cancer or sarcoma.&#x201d;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">&#x201c;The publication of this manuscript in </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;font-style:italic;min-width:fit-content;">Nature</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">, strongly underscores the relevance and novelty of our clinical and biological findings,&#x201d; said Francesca Barone, MD, PhD, Chief Scientific Officer of Candel. &#x201c;The molecular construct of CAN-3110 makes this virus unique as a next generation viral immunotherapy candidate, combining in a single agent potent oncolysis and immune activation. Of importance, patients with recurrent HGG who had pre-existing antibodies to HSV-1 virus (66% of the patients) had a median overall survival of 14.2 months. In these patients, we observed clear evidence of immune activation in the tumor microenvironment. Those without antibodies (34%) had median overall survival of 7.8 months, which is in the same range as historical survival</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">times. Different from conventional immunotherapy, CAN-3110 is designed to expand but also diversify the immune response. Accordingly, we observed increased diversity of the T-cell receptor repertoire after a single injection of CAN-3110 in recurrent HGG patients. We have started to evaluate the effects of repeated injection with CAN-3110, which has the potential to result in the HSV-1 seroconversion associated with improved survival.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">About the phase 1 clinical trial of CAN-3110 in recurrent HGG</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">This investigator-sponsored study is led by E. Antonio Chiocca, MD, PhD, Head of the Department of Neurosurgery at Brigham &amp; Women&#x2019;s Hospital and Professor at Harvard Medical School. The clinical trial comprises three arms. In arm A, 41 patients with recurrent HGG were treated by a single intratumoral injection of CAN-3110 (dose ranging from 1x10</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:'Arial',sans-serif;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> plaque forming units (pfu) to 1x10</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:'Arial',sans-serif;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> pfu), including nine patients with multifocal/multicentric, deep or bilateral tumors associated with poor survival.  After observing this regimen was generally well tolerated without dose-limiting toxicity, patients in arm B (n=9) were treated with a single dose of cyclophosphamide (24 mg/kg), two days before CAN-3110 injection at doses of 1 x 10</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:'Arial',sans-serif;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> pfu (n=3) and 1 x 10</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:'Arial',sans-serif;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> pfu (n=6). The rationale is based on findings in mouse models, where cyclophosphamide improved viral persistence in injected tumors. In arm C, supported by the Break Through Cancer foundation, two cohorts of 12 patients with recurrent HGG will receive up to six injections of CAN-3110 over a four-month period.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Early results from the phase 1 clinical trial were presented in May 2023 at the American Society of Gene and Cell Therapy 26</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:'Arial',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> Annual Meeting. The oral presentation highlighted that in arm A (n=41), treatment with a single dose of CAN-3110 was generally well tolerated and resulted in median overall survival (mOS) of 11.8 months as of the data cutoff date on April 20, 2023. In addition, at the same data cutoff date, median overall survival in arm B (n=9) was ongoing at 12.0 months, supporting the encouraging clinical activity of CAN-3110 observed in in arm A. Of note, responses were shown in both injected and uninjected lesions in patients with multifocal disease. Analysis of post treatment samples demonstrated evidence of persistent HSV antigen expression and replication in uninjected tumor tissue associated with CD8+ T cell infiltration, which may explain the clinical responses observed in uninjected tumors.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">About Candel Therapeutics</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel&#x2019;s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. This leads to in situ vaccination against the injected tumor and uninjected distant metastases.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Candel has established two clinical stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in NSCLC (phase 2), pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma. In addition, Candel&#x2019;s enLIGHTEN&#153; Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: </font><font><font style="white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">www.candeltx.com</font></font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">This press release includes certain disclosures that contain &#x201c;forward-looking statements,&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including the timing and availability of additional data, the possibility to use early biological readouts as predictor of clinical response and expectations regarding the therapeutic benefit of its programs, including the potential for CAN-3110 to extend patient survival. The words &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;could,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue,&#x201d; &#x201c;target&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#x2019;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of current and future development programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; expectations regarding the therapeutic benefit of the Company&#x2019;s programs; the Company&#x2019;s ability to efficiently discover and develop product candidates; the Company&#x2019;s ability to obtain and maintain regulatory approval of product candidates; the Company&#x2019;s ability to maintain its intellectual property; the implementation of the Company&#x2019;s business model, and strategic plans for the Company&#x2019;s business and product candidates, and other risks identified in the Company&#x2019;s SEC filings, including the Company&#x2019;s most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company&#x2019;s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Media Contact<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Aljanae Reynolds<br>Director<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Wheelhouse Life Science Advisors<br></font><font style="color:#ed7d31;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">areynolds@wheelhouselsa.com</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Investor Contact</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Sylvia Wheeler</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Principal</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">Wheelhouse Life Science Advisors</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ed7d31;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;">swheeler@wheelhouselsa.com</font><font style="color:#ed7d31;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:'Arial',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img160460863_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160460863_0.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   ?V@
M P $     0   .(     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ "#_V@ , P$
M A$#$0 _ /[\**** "BBB@ HHHH **** "BBB@"*8R"%FA W[3M!Z9[5\O\
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MPVDJE-Z57T;]/-RL[V8M%%%?M1^(A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?_]+^_"BBB@#PVY_:$^&5C\4-1^$^IWIM=3TK2H]8O7N$
M,5M';R,$!,[83.2,@GN*]HL[RSO[:.]LI$FAE0/'+&0RLI&05(X((Z$5Y%\;
M?@7X#^//@B]\">-H9!;7WD^=/9L(K@>2XD0;\'(##.""/:OSJ\0Z5^T9^R#X
M_P!1^)5S?R77PB\*Z-':Z9H,,R2221+ D$$.UEWB03_.\I.-O<C@?GV=<38[
M*JKJ8NCST&_B@M8)MMN2O\,4M6MWT/T3)>&<!FU+V>$K^SKI?!/:;T24'_-*
M3TBUHNI^OF,5Y/\ ''X?7GQ7^$OB#X<Z?>-83:QID]A%=KG]VTJD G')'J!S
MC.*^:_V>_P!N[X;?%[X877Q&\;?9_"$=EJ/]F3)JER@ADE*AU\J5MF[*GD8!
M&.F,$_:>A:_HWBC1X/$'AVZ@O;*ZC$UM=6SK)%(K="K D'/J#7N9?G66YS@_
M]GJJ<*D7ULW%W6VZZ]#PLQR7,LDQEL32<)TI+=72DK.U]GT>[/RJ_83_ &&?
MB%^S+X\U7XD?$O4M-5&TU[""VL)':,H75VDD9U0  +PN#UR<8Y_1[P!\9OA=
M\4Y[NW^'NO:;K#V+^5>)83I,8CTPP4Y&2#@]\<5M?$7P=;_$/P)JW@>[FEMH
M]6T^>P>>$X>,3(4++[C.17PE^Q?^PD?V4O$6K^,]<UU=4N;NU%C L,1@ACME
M;>6<,3ER0/91G!.>/BLER"OP[5P>49-A>;#/F<YN6L7NO6Y]MGG$5#B.GC<X
MSO%\N*7*J<%'W9+9Z]+'T-^T!\/M%LM U3XQ>$?"FEZWXVTO3I9M&N)K='N/
M/B4F/:V-Q(/( Y[ C-?/W_!/;XL_M'?%#PYK]Y\?+66*.VNHETJYN;3[')(6
M#>:@0@95,+AL=R"37V1\/OC7\*?BQ=W]E\/-<TW5Y=-D$5['9S+*8F.0-P!/
M!((!Z$@C-?)_[:'PC_:H^)&M^&I_V?->_LBSLYW?4XX[AK1BY9/+E? /FHH#
M9C.<D]#GB^(,-[&O3S_+)2JQC>]*E:U1R=N9OJX]?0RX>Q"K4*G#^90A2E.U
MJM7F3I**ORI6=E+Y+7K<]$_;&_99/[5/@*T\)PZQ)I$MG?+=Q2%#-"^U2I61
M RYX.0>QYQ7L?P(^%5O\$/A/H_PNMKN6_32;8PF[F&UI&+%R=N3@9)P.<#%>
MAZ'<B2RCLY[J.ZNK>-([MXR,F4*-Q*CID\X]Z^,+;PS^V&W[7$FO7>IVP^&P
M@(CLPT7(\O&W9M\WS/,YW$[<=Z]K'8#!X+,(9K1PDIUJ_+3;CKRK>[ULDNK1
MY&!S#&X[+9Y/6QD84:'-5C&6G-+:T=+N36R,WX\?LV?LVQ?&'2_VEOBWK<NC
MW%I<6T*175W'!9W$\+$PAMZ[L@GHK#-?;&M^)-,T'PI=^+G8RV=G82:@6@^?
M?%$A?*8^]D#CUKQO]HOX&?"+XV>#X;7XRYCT[2KA=26[^T&V6%D!!9I"=NTJ
M2#GL>U>K:-<^#-.\#P3:3-:G0[73@(IED$D M(H\ [\D% @Y.3FNG+<J6$QN
M,=&E"G&=I77Q2EU<EY'#F>;_ %S!8)5ZTZDJ;<>5_#&.EE!]WK?3L>%_LO?M
M3^%/VI-"U+7_  O87]@NF7GV2:.^506+#*LI1F7&.W4=ZXC]M'PK^S?\1O#^
MC^ _CYKO]B/<ZBK:1)'.L,SS?=(&Y67!S@DK^->]_!;Q-\&_%OA:36/@F^D/
MI;74B3-H\<<47G@_/N"*OS>I(KS;XM> _P!F;XU_$G2O!/Q(?3[_ ,3:./[2
ML=+-T8[E8\YW-&K LA(S@C%>=F&'Q&(R..'K5*=>=2R;EI"=WY/MMYGK8#$X
M;#9]+$T*57#PIMM*.M2%EW:77>ZV/=/ASX+\/?#SP1IG@GPJ&_L_3K5+>T+M
MO)C4<$MCDGK7A/[1/[(/PI_:;OM)U#X@&^2;29/W;V$HC\R,G+1/N5OE..HP
M1ZU]//;"WT_['8D1;8O+AQT3 PO'M7Q=^R[\'?VD/ASXY\4:Y\:?%8US3M3N
M"^E6HE>81#>2&PZJ(_E(&U>*]3/,)0G'#Y55P3J4IZ/1<L%':^M_0\K(L=B*
M4L1FM''>RK0U6KYI\SM*UE:^NMSZQ:;PC\-/"<8NY[?3-)TRW6(2W,@CCBC0
M;1N=S@=AS7Y=ZW^QU\1_B9^UU8?M*>%?%EC<^&6O;?4X)8;AWF$,0 ^SQJ@,
M91L8SNQ@\C-?3OQPMO@C^UI!K7[+C>)5M]:LS'=75O9,&F@:%L_-&2%<*3AE
MSQQT->V_ 'X*Z%^S_P#"_3OAAX>N;B\M]/#_ .DW. [O(Q=CA>%&2< =.E?/
MYSD=+/,33PE6DI8:BU*,XSM:<7\-ET7J?0Y-G];(L+5Q=&M*.*K)QE"4+ITY
M*_-S/JV>T(NU0/0 &G445^HGY4%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?_T_[\**** "LO6-'TOQ!IL^CZY;0WEI<QM#<6URBR
MQ21L,,K(PPP(Z@BM2BE*"DG&2NF5&3333LT?D=^W+^P;XE^*>D^&;;]GZTTJ
MPL]$^U1RZ&FVS@+7)0^>F %+C9@YY(QC.,5X#K_[0OQ-_P""<7@3PK^SW;:?
M::QJ3V\NMZG=W,D@MHQ=3OBUM<*"=N#ECC!/"\U^]I947+' '<\5YWXM^&/P
MT^),MM>>,]'TO6'LW+6DMY#'.8CD'Y20<<@$U^+<1>$<?K.(S/(Z_P!7Q55)
M<V\4E:Z2MU22_0_;N'?&"?U7#95GU#ZSA*3E+EVDY.]FY7ULVW^K*G@/XHZ!
MXO\ "6A>(+Z6#3;K7-.M[^'3;N94G7SXPY3:Q#$J6P<#WKN];TFTU_2+G1M0
M!:"[@>WE"D@E)%*L 1R.#UK\ROC[^P5XS^+/[36D?&32?$<=EI5HUF9;4^8+
MBV%F^XK;[?E ?ZC!]:]1L/VU))_VMF_9?'AR\\F(^0=8R3F00>=OV;?]7VW;
MNM>_A>,ZF'G/#YU1]G%S5.$KW]JVGK9?#<^<Q/!5/$TX8C)*WM9*G*K4C:WL
MDGM=OWFO(W_V7OV)/AW^RKJVK^)/#^H7^H3ZBBQ"2]VHMO;1MO" )C)R!ECZ
M<8R<_0OP]^-/PL^+,^HV7P\URPU>33)!#?I92B0PN20-V.F2#@],@\UZ5*+2
M^CDL9&1PRF.6,$'AA@@^E?$D?@'X ?L ^!_$GQ6T+3K]8+V6%[U("US*Q:0B
M.*,8^5 \AQGIW/%=U++X9'2HT<OIPIX6'.ZFKO'JK;];WN<57,:F>U:];,:L
MZN+J<BIV2M)[.^W2UK+U-#X/_LY^"OV5_%GBOXIZSXLN)H?$EWYD@UB5(+>W
M,DNY5W.V&;+;5/''&*]=_:"C^,VK?"F[_P"&=KJQB\0RM"]G<7>QHC$6&\@L
M"F2F=I((Z55\2>#OAC^UI\']//B:SGGT?5H[;5;>&7=!,A4B1-W0@CH0:]OT
M?2K'0-*M]%TN,1VUI EO!&"<)'&H55Y)Z  =<UU99D5..&J8+"15.A-7C*,G
MS7DVV]=NZ=^IR9GGM26)IXW&2]IB(2M*,XKEM!)13MOM9JW0\HO?AE)\4_@M
M'\-_C@L=[/J&F1V^N_9&,223;1YAC*X(&X9&*ZCPI\,?!O@SX>P?"[1K4+HL
M%DVGI:2L7S X(8$DDG<"<_6O0F94&6( Z\\5\R?&']M#]E/X @?\+C^('A3P
M\6#$)J6I01.=HR?D+Y)Q[5])ALBH\ZJ1I\T[<O-O)Q[-]3YRMG6(=-TN?EAS
M.7*M(J7=+II^!ZA\+?A!\/\ X,>'?^$4^'&G0Z=8M.]P\<6X[I'Y+$L22?QJ
MO_PICX;+\36^,*Z7;_\ "1&U^Q?VE\WF&+TQG&<<9QFOSSC_ ."X/_!+:6__
M +.'QA\*A]P7>9R(^O\ ?V[:^R/@_P#MC_LK_'P'_A3OC_PIXB*XRFF:E;SO
MEATVA\Y]JZ9\,TZ=*G3>&M&&L5RV4>UE;2QF\\Q$ZM2M[=N4T^9W=Y7WN^M_
M,9^TK\.?C7\0]$TJR^#/BC_A&I[;4XI[Z7R@QFMU(W*#AL?3OWKT#XA_%/PO
M\"/AXOC+XHW["UM?)MKB[2%G:25\*"(XP3ECSP*]:#!AN0@C&0165K.A:+XC
ML&TO7[6WO;=BI:"ZC62-BIR,JP(X/3BO+JY4X3KXC#2:J327O7<4UM[M_OL=
MU+-XSA0P^)@G3@V_=24FGNN:S?I>YX=\/O@5\%-/\?7/[0'@O3436-?M_-FU
M#?)^\2;#%A$QVH7P"V ":^A_:HHHH[:-88E5%0!%51@ #C  J:NO*\MHX6GR
M4J:C=W=E9.3W=O-G'F>95<54YZLW*RLN9W:2V5_)!1117>CSPHKC?'_C_P &
M?"OP7J7Q%^(6I6ND:)HUI)?:GJ=_((H+>"($L\CM@ #_ .L*\R_9R_:C^ W[
M6G@3_A9?[/GB;3/$^C+<R64EYILHD6.>(C?'(O56&0<$="#W%:J$FN:V@K]#
MW^BBBLAA1110 445\6?&_P#X*&_L;_LX?%S2/@7\:?'NA:!XJUP6SZ?I5_.$
ME*WDIA@9STC5WR%+$ \GI6M.DYNT%=^0<R6K/M.BHHW24"6)@RL-RE<$$'N#
MZ&I:R **** "BL[5]8TO0-,GUK6[B&TM+6)KBYN;EQ'%%&@W,[LQ 50!DDFO
M!M-_:X_9AU;4(=*TOQ_X1N+BXD6&WACU6V9Y'<X4* Y)8GC%:1I2:T0KGT51
M2 @@$'Z?Y[^QI:S&%%%8OB+Q'H'A'1;GQ)XIO+;3["SC,MU>7DJPP0HO5G=B
M ![FFD!M45\S_P##9?[*1Y'Q#\&_^#:UR!Z?ZRC_ (;+_93_ .BA^#O_  ;6
MO_QRMOJU3^4GG7<^F**^;(?VQ?V5[B98(?B%X/9W8*JC5K7))_X'7LWASQ[X
M'\81B;PKK&F:DK=#8W44_P"6QC4RHS6Z'='6T4@(/2EK(84444 %%%8^O^(-
M"\+:/<>(/$MW;6%C:QF6YN[N18H8D'5F=R% ]S32OH@-BBOFC_ALG]E/K_PL
M/P=_X-K7_P".4G_#9?[*?_10_!W_ (-K7_XY6RPU3^4GG7<^F**^9_\ ALO]
ME/\ Z*'X._\ !M:__'*/^&R_V4_^BA^#O_!M:_\ Q='U:I_*'.NY],45XCX+
M_:2^ ?Q$UV/PQX&\8^&]6U"5&>*RT_4;>>9PGWMJ(Y8X]J]NK*=-K=%7"BBC
MGM4@%%<!X_\ BI\-_A7IT.J_$C7=*T.WN)/)@FU6YCMDD?&=J-(RAB!V'XUS
MO@+]H+X(?%'5WT'X=^+/#VMWJ1&=K73+Z"XF$8X+[(W)P.YQBK5*5KV%<]AH
MHHJ!A1110!__U/[\*2OF3XE_$WXU^#/%FICP]X335O#]AX3N-6@NX;C_ $FY
MU2)CY=FL6,_.HSGKZ5\HW7_!0WQ/X6?P-H?COP'J]GJ_BS)N[1,YM5:Z:V3:
M& 9V(7S-N 0I'K7Q>;<?Y=@9NGBY.#7>,K;I:.UM6]/GV/M<IX S+'04\'",
M[]%*-]F]5>^B3N?J3D'I1VYKX.^'_P#P4$^"_CWXL:Q\++4W=LVDQ7DS:E<H
M%M9%T\'[05.<@* 3E@,@5O? S]NWX'?'[QW<?#_P=<W*7R1R36OVN%HENHHN
M7:(G^Z/F(.#CGH*K">(>25ITZ=/&0;FW&*OJY*UTO3]4/%^'>>8>%6I5P4XQ
MIQ4I.VBB[V;];/[CTO\ :K\)_$GQO\!?$'A?X1W)MM>NK94LY%?RF(#J9$63
MC:SIE0V>,CD=:^;O^"=OPB^/?PE\!ZQ:?&^XN";N_273=/N[@W,D"JI$C%]S
M8$C8PN>QX&:^V?"_Q0^'GC?4[K1?">LZ=J-U8L4O+>TG21XFZ8<*3CD8^O%=
M]N4Y"D''45G/A?"8K-J.=PK2<J:<4E+W'?>ZZL=/BO&83**V0RH14:DE-MQ]
M]6M:SZ+3^KGQ#\-OVZ?AK\3?VA+_ /9_T2VODO+22Z@BOI8P(9IK//G*O)88
MVM@D8./I7V(WA[0?[4;7Q:VR7[Q>0;WRU\\IZ>9C=CGIG%>=^'?@)\(/"?CV
M\^*'AW0;&UUZ^W?:=0B4^8_F??(!.%+?Q$ 9[FOGS]K/X._M&_$[Q3X4U'X)
M>)ET*RTRZ:75H3(T9DRR%'PJGS JAQL;@DURT\1FV P%6MCX+$U%-N*IJSY6
M]-[:I/5G74P^49ACZ-# 5'A:;@E*51W7,EK\*V;V+?PG_9NU_P""WQ;\8_&K
M7_%>I:S9:NDD\.E2ARL"[O-/!9@2@78FT#Y?>O5_@A\9?!7[3WPZ?Q7I-A<C
M3WNIK&6TU:WVEFA('*/D,#D$?KR*YSX\?M)VGP,\0^%_#%WH>K:P_B2^^P^;
MI\6](,%06?G_ &N@YQGTKZ5TZRM+&T6&PAC@CY81QJ$ W$EN ,<YR?6NK(L)
MAJ.(J8+ 5+0IM\\7=OFG[R=V^U^^YS9[BL36PU/&YA3?/52]G/1+EA[K7*EZ
M:^19@@AMH%@@4(B *JH  H P !T  X %?*W[8O[9_P !?V'/@_>_&7X^:Q%I
MEA;H5M+4?/=W]QCY(+:(?-)(V. .G<@5[+\7_BMX)^!OPRUOXN?$:]CT_0_#
MVFSZIJ-W*<*D,"%V^I., #J:_P J3_@I]_P49^)__!1W]HS4/B;XFN;J#PO8
M7$MKX,\.LY\FPL =JR,@X,\P&Z1NHSM!P*_7>&>'GCJFND([O]$?F>:YDL/&
M^\F?=W_!0C_@XE_;%_:\U>\\+?!F\N/AKX(+M';VFCR;=7NHNF;F\7E"W4I%
MC'3<:_ :]N_$/B[5WO=1FOM5U&X;+S3O)=7$K$]V8LY/U-?L)_P29_X(X?&/
M_@I?XS;7)Y)O#7PZTJY":SXHEB+&9Q@M:V2G DF(ZG.U,\GU_P!!3]D__@E-
M^PM^QMH5K8?"3P'H\FI6ZH9?$.M0)J&IS2+U<S3*VPY&<1A0.E?H&.S[ Y5^
MXH0O+LOU9\]1P&)QG[RK*R/\I63X/?%J*R_M"7POX@6 +N\UK"<)CUSLKDM,
MU/Q#X0U>/5-&N+[2M0@;='<VTDEK<1L#P0R%7&#[U_M.MHNCO!]F:SM3&1M\
MLQ)MQZ;<8Q7YR_M7?\$COV#/VP]#N;+XH^ M(M=3F1_)\0Z!"FG:C%(W1_,@
M"K(0><2*W]:\ZAXBP<K5J-EY.YU5>&FE>E/7S/XHO^"<G_!QO^U1^REJECX%
M_:-GN?B/X(WI!))?/NUJPB&!NAN#_KPH_@D^8]FK_0,_9I_:6^$'[6_P>TCX
MY? [58M8T#5XM\$\?RO'(/\ 60RH<,DD9X93T-?PA_%W_@UT_:R\.?M5Z5\,
MOA;J%IK/P[UBY,S>-9RL;Z5:*V72[AY)F"\+LR'/I7]Q?[%G['_PJ_8:_9]T
M7]GOX00LFG:5&9+FZF),UY>2X,]S)VW2-S@< <"O"XMEETU"KA6N:6Z6UO\
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M.-O7?DJ_VNC_ (D<^+_A3]&?Y<26\+,$5%))P/E'4_A6O_PBNM9_Y!MWZ?\
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MQL20:)#@W3<'(\YBL0/<;J_I5U"_M-+L)]3OY$B@MHGGFED(5$2-2S,Q/
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MY_\ ^4IU_P#]B%X=_P#1<M?Z5@ZCZU_FI_\ !S]_RE.O_P#L0_#O_HN6ON.
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M#%?1\ _[E7]?T/,S_P#CTOZZG^T/X(_Y$G1_^P9:_P#HE*Z>N8\$?\B3H_\
MV#+7_P!$I73U^5UOCEZGUT?AB%?BA_P<.?\ *(WXK?\ 7#2__3C;U^U]?BA_
MP<.?\HC?BM_UPTO_ -.-O7;DO^]TO5&&*_AR]#_,W^!W_);/!W_8U:5_Z5QU
M_LZI]Q?]T?RK_&*^!W_);/!W_8U:5_Z5QU_LZI]Q?]T?RK[KQ'_BT/1G@<-?
M!4]1U!Z445^9'TQ\\?M3_LU_#+]KCX%>(?@+\6;%+W1]>L)+9U(^>"4KF*>)
MN=LD;X92!P17^1Y^U3\ O$/[+?[17C']GSQ26>Z\*ZY<:8)B,>? IW03=O\
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MC;&_P:ENS_(_S4/@3_R73P3_ -CCH?\ Z70U_LN>'O\ D V7_7I%_P"@"O\
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M_:;N[==JRF/.X0Q,0SOC ''4U_E9>,/%?BKXI>.M2\:>)9IM0UO7]4FU"\E
M+R7%W>2EVP.I+.V !]*_3/#_ "R:G/%S6B5D?,\1XI<JHK=G]9__  :._"Z\
MU/X\?$SXNR1M]ETSP]:Z1%+C@SW,I=ESZA!FO[RCR!]<U^(G_! _]A>__8F_
M89TJ/QA;&V\4^,Y1XGUV&1=LD'G*/L\#9YRD>,CU-?MV*^3XHQD<1C:DX[+3
M[CU\KH.G0C%BU^'7_!Q5_P HH_B'_P!=-+_]+X*_<6OPZ_X.*O\ E%'\0_\
M?TO_ -+X*X\C_P!]H?XH_FC7&_P:GH_R/\S+X:>'K#Q=\2_#GA+5-XM=5U_3
M=,N3&</Y-W<QPN5/8[6.#ZU_H,Z7_P &KO\ P3LOM-M[V74?'(:6".5@-2&
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MC36_VR/BY8?MFP?L]VGA5GT)[F*UDOS#-YS)+&':[60?N_*0G!&.QYS7T_\
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M<>:>.F.F?^!5^7?[7_\ P=C?#W3=)N?#_P"Q9X/OM2U"2,QQ^(/%ZK;VT)/
M=+2)F>0CJ-S@>HK^.R/]D#]K*2[_ +/B^&7C\S$[?+&@W^<_]^?ZU]J_ +_@
MB+_P4N_:$U2"TT#X::KH-I,RA]3\6%=+MXE;^(K)F8_\!C/X5ST^%<JH/VE2
MI=+NU8VGFV+J+EA"S]#Y2^)?[<_[5GQ8^/L?[3?C3QIK4WC&VOEO[#4HYVB%
MFR-N2.WC4A$C7H$ P1UK_3K_ ."2W[2?QY_:O_8A\*?&+]HWP_)H/B.]C>%S
M(AB_M&"'"Q7PB;YD$X^;;^(P#7Y"_P#!-_\ X-E_@C^SGJ]C\5OVNKRU\?\
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M359RHJ-1:K0D'4?6O\U/_@Y__P"4IU__ -B'X=_]%RU_I5].:_@R_P"#B/\
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MYDU<]S+L14JP<JD;,DHHI",U\Z=Q_$G_ ,'@)(N/@>1_?\28_P"^+&OY[O\
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M.TOPK*_PSL-'M1=>*3=VJQ*\6@7%FR" R^>7$[JG$>.<]*_6O_@JQ^PWI/\
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M** "BBB@ ]SV]:,8XZ\_YQ110 4HZTE% !TZ#&>N,=?UHHHH __4_OPHHHH
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>cadl-20231018_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-10-18T08:23:35.7023+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cadl-20231018.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cadl-20231018_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-10-18T08:23:35.8995+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cadl-20231018.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-10-18T08:23:35.7311+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.candeltx.com/20231018" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cadl="http://www.candeltx.com/20231018" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cadl-20231018_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cadl-20231018_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140451328346384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 18, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001841387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 18,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CANDEL THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-40629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2214851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">117 Kendrick St<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Needham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">916-5445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CADL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>cadl-20231018_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cadl-20231018.xsd" xlink:type="simple"/>
    <context id="C_e1b713f4-5bbe-4282-a00b-ee69485c377a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001841387</identifier>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_5b213b4e-faa2-40c8-b467-d308abbf3579">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_c63f2a9c-25fc-4bb0-a292-64e4c12fb164">0001841387</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_f012b128-66e5-4e45-a436-d86b8d3e97a9">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_bd957721-00a8-4e6a-862c-26911a8bd8a1">2023-10-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_8841de57-9ee6-4dac-99ce-949c3e0012cb">CANDEL THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_778ce643-7e59-4682-bb17-35dba6ca534a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_134e08b9-9b3b-4425-bd87-4169f825d4e3">001-40629</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_f072fa2e-efff-4e50-b147-4b87f7297534">52-2214851</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_c8b00f95-9fc7-4a6b-8366-b9136a949a0d">117 Kendrick St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_22d027b6-f73d-49a5-8bd0-5ad09b0c6db4">Suite 450</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_71a31c3d-8f90-4aec-a5a8-cd360fe29449">Needham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_b370751d-4500-4837-87d6-3cd8547b6e56">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_8c341ba3-9206-4a94-8c2d-3652210b5438">02494</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_5da723cb-bd83-4142-b948-e4ac764121fb">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_55c5dbce-f0c3-4987-b212-7beafaee0d75">916-5445</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_e5cb253d-2e57-4186-8152-7902df8578b7">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_25fb8ca8-8525-4458-b7fa-ae3b79fe7834">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_9aaf36e7-2e2b-4cf7-966f-edc72d5528b9">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_117cc848-3754-40e6-97d2-9e9a0e158640">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_c6b76e03-d395-41b0-892e-04d845258ec4">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_0d6a56ce-2a73-496b-b2c3-c3ee00727a80">CADL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_9525bc29-bbbc-4116-a798-ac8b723a6463">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_20b3a2b0-81b9-4adc-8c07-4fb5fe12b9b9">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_e1b713f4-5bbe-4282-a00b-ee69485c377a"
      id="F_17c9597d-4e13-4d96-ac67-0061336087f0">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MXYS%M6"XSG@TGTP?R>KS]&6TF'Y=S<;+*S*;CV\0QE[)V+N$<98$4J52Y<9
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( .=;4E=ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #G6U)7)!Z;HJT   #X 0
M&@              @ 'Y$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " #G6U)799!YDAD!  #/ P  $P              @ '>$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   H%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cadl-20231018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="cadl-20231018.htm">cadl-20231018.htm</File>
    <File>cadl-20231018.xsd</File>
    <File>cadl-20231018_lab.xml</File>
    <File>cadl-20231018_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cadl-20231018.htm": {
   "nsprefix": "cadl",
   "nsuri": "http://www.candeltx.com/20231018",
   "dts": {
    "inline": {
     "local": [
      "cadl-20231018.htm"
     ]
    },
    "schema": {
     "local": [
      "cadl-20231018.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cadl-20231018_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cadl-20231018_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_e1b713f4-5bbe-4282-a00b-ee69485c377a",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cadl-20231018.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1b713f4-5bbe-4282-a00b-ee69485c377a",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cadl-20231018.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Act File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.candeltx.com/20231018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-23-053894-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-053894-xbrl.zip
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M1U!6UTIB>9GT8A$52M;S,4GJWET/92$P_,)$;YP)?)V1\7+;\\W]8ZF]?^S
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M9N<14&LU7]06;Y0NQ[BDM;"CJ);_UE3P)<?"]5>@;\R>04_M!B)-CK(N!SO
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MBT+.'9.*H,9^V@_!T\B4;![7+Q 6V5>$VPU#>";([0<\$[!7B&JR_<\PFZ_
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M%#VO_0+33G7BR+.,85>V-(55;"<+UI$^FL>C>7QIYO&J2(#U%NJJB['.''P
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MB&URXR#I+$C:-I)NV_(H_(T]O$H6G?;[=Y4_(7=%Z -\P5->:X8MLL&?%*/
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MV1[]???O_O9LC_\R_/\#4$L! A0#%     @ YUM25PC] 1P#%   Z-@  !$
M             ( !     &-A9&PM,C R,S$P,3@N:'1M4$L! A0#%     @
MYUM25QJK<C4, P  GPD  !$              ( !,A0  &-A9&PM,C R,S$P
M,3@N>'-D4$L! A0#%     @ YUM25[R,T=0R!@  .CH  !4
M ( !;1<  &-A9&PM,C R,S$P,3A?;&%B+GAM;%!+ 0(4 Q0    ( .=;4E?U
MX#I0S@0  +DL   5              "  =(=  !C861L+3(P,C,Q,#$X7W!R
M92YX;6Q02P$"% ,4    " #G6U)7C!HDEK<6   @?@  #P
K@ '3(@  8V%D;"UE>#DY7S$N:'1M4$L%!@     %  4 00$  +<Y      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
